Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphom...

Lead sponsor: Sun Yat-sen University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Qingqing Cai, MD

CONTACT

0086-20-87342823 caiqq@sysucc.org.cn

Related studies

RECRUITINGPhase 2

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05833724 · Relapsed or Refractory Peripheral T-cell Lymphoma

TERMINATEDPhase 1/2

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

NCT04362007 · Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 24, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment44

Start dateMar 2020

Last updatedApr 24, 2020

Condition

Relapsed or Refractory Peripheral T-cell Lymphoma

Locations shown

Guangdong General Hospital

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 24, 2020Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions